Lantern Pharma Inc.
$3.91
+0.1240 (3.27%)
Join the Lantern Pharma Inc. Investor Community
Get the latest news and company updates delivered straight to your inbox. Subscribe for free to stay ahead of the story and follow Lantern Pharma Inc. as new developments unfold.
Company Overview
Lantern Pharma is a clinical-stage biopharma company redefining oncology drug development through artificial intelligence. Its proprietary RADR® AI platform leverages over 200 billion oncology-specific data points to rapidly identify drug candidates, optimize patient targeting, and de-risk clinical trials—cutting early development time and cost by up to 70% and 80%, respectively. Lantern’s pipeline includes three clinical-stage assets: LP-300 (Phase 2) for NSCLC in never-smokers, LP-184 (Phase 1b/2) for DDR-deficient solid tumors and multiple CNS cancers, and LP-284 (Phase 1) for aggressive B-cell lymphomas. The company also advances CNS oncology programs via its wholly owned subsidiary Starlight Therapeutics and is developing novel antibody-drug conjugates (ADCs) in collaboration with global partners. In parallel, the company is extending its AI capabilities beyond internal drug development with the launch of withZeta.ai, a multi-agentic AI co-scientist platform currently in beta testing with over 25 biopharma and research organizations, representing a potential new commercial avenue for its technology. With 12 FDA designations, over 100 issued and pending patents, and partnerships spanning Johns Hopkins, MD Anderson, and Bielefeld University, Lantern is positioned to unlock value through precision-driven clinical execution and strategic collaborations.
Articles
AI, Precision Oncology, and a 1,400% Upside Potential: The Case for Lantern Pharma (NASDAQ: LTRN)
April. 10, 2026 9 min read
Lantern Pharma (NASDAQ: LTRN) is a clinical-stage biopharmaceutical company using artificial intelligence to discover and develop precision oncology therapies. Its lead asset, LP-300, is currently in a Phase 2 clinical trial targeting never-smoker non-small cell lung cancer (NSCLC)...
Read More
Value Proposition
Lantern Pharma represents a differentiated investment opportunity at the convergence of artificial intelligence and precision oncology, offering a capital-efficient model designed to repeatedly generate high-value oncology assets. At the core of this strategy is RADR®, the company’s proprietary AI platform, which leverages over 200 billion oncology-specific data points to identify drug candidates, optimize biomarker-driven patient selection, and improve clinical trial success probabilities. This approach has enabled Lantern to reduce early-stage development timelines and costs by approximately 70% and 80%, respectively, while rapidly advancing multiple programs into the clinic.
The platform’s predictive capabilities are now being clinically validated. LP-184 has successfully completed its Phase 1a trial, demonstrating a ~48% clinical benefit rate and durable responses in heavily pre-treated patients, supporting advancement into multiple biomarker-guided Phase 1b/2 trials across high-value indications including TNBC, NSCLC, bladder cancer, and glioblastoma. LP-300, currently in the Phase 2 HARMONIC™ trial, targets non-small cell lung cancer in never-smokers—a $4B+ market with no specifically approved therapies—while LP-284 is progressing in aggressive lymphomas and soft tissue sarcomas with orphan drug positioning. Together, these programs represent multiple shots on goal with meaningful clinical and regulatory catalysts.
Beyond its internal pipeline, Lantern is expanding the commercial potential of its AI platform. The recent launch of withZeta.ai, a multi-agentic AI co-scientist system currently in beta testing with biopharma partners, introduces a potential new revenue stream through platform licensing, partnerships, and data-driven services. This evolution positions Lantern not only as a drug developer, but as an emerging AI-enabled oncology platform company.
With over 100 issued and pending patents, 12 FDA designations, and a lean operating structure, Lantern maintains a strong foundation for value creation. Its ability to generate and advance multiple targeted therapies at a fraction of traditional biotech costs—combined with expanding platform monetization opportunities—creates a compelling asymmetric risk-reward profile. For investors, Lantern offers exposure to a scalable, AI-driven engine capable of delivering repeated clinical and strategic inflection points in oncology.
Investor Presentation
Investment Highlights
AI-Driven Drug Development Platform with Transformational Efficiency
- Proprietary AI engine – RADR® – integrates 200B+ oncology-focused datapoints to streamline and de-risk oncology drug development
- Launched 12 programs in 24 months, reducing time to Phase 1 by ~70% and early-stage development costs by ~80%
- Patient response predictions validated at >88% accuracy; AI powers biomarker-guided patient selection and combination strategies
- Launched withZeta.ai, a multi-agentic co-scientist platform currently in beta testing with biopharma partners
Diverse Pipeline Anchored by Three Clinical-Stage Oncology Programs
- LP-300 (Phase 2): Targets relapsed NSCLC in never-smokers—a $4B+ global market—with demonstrated >2x improvement in median survival for subgroups in prior trials. Currently enrolling patients in the multinational Harmonic™ trial
- LP-184 (Phase 1b/2): Designed for DDR-deficient solid tumors including pancreatic, bladder, TNBC, and glioblastoma. Fast Track and Orphan Drug Designations; monotherapy and combination trials underway. Phase 1a completed with ~48% clinical benefit rate and durable responses; advancing into multiple biomarker-guided Phase 1b/2 trials
- LP-284 (Phase 1): Novel acylfulvene analog for aggressive B-cell lymphomas (MCL, HGBL) and soft tissue sarcomas. Orphan Drug designation in place; potent single-agent and combination activity in preclinical models, including Ibrutinib-resistant tumors
Multiple Platform Expansion Opportunities
- Wholly owned Starlight Therapeutics subsidiary advancing STAR-001 for CNS and pediatric brain cancers; holds Rare Pediatric Disease and Orphan Drug designations; recent FDA IND clearance for pediatric trial
- Cryptophycin-loaded ADCs showing sub-nanomolar potency; highly stable constructs with superior drug-to-antibody ratios vs. MMAE benchmarks
- Early-stage pipeline includes ER+ breast cancer program & multiple RADR®-identified candidates with combination & licensing potential
Strategic Positioning with Strong IP and Regulatory Tailwinds
- 12 designations across the pipeline, including multiple Fast Track, Orphan Drug, and Rare Pediatric Disease designations
- 100+ issued and pending patents across RADR®, LP-300, LP-184, and LP-284—extending exclusivity through 2044
- Modular, reusable AI infrastructure allows for rapid asset generation without redundant infrastructure or fixed costs
Capital-Efficient Model with a Clear Path to Value Creation
- $10.1 million in cash, cash equivalents, and marketable securities (as of Dec. 31, 2025)
- Active collaborations with Johns Hopkins, Bielefeld University, and others provide validation and external development pathways
- Multiple catalysts: Phase 1/2 trial readouts for LP-284 & LP-300, Phase 1b/2 initiation for LP-184, and ADC IND-enabling studies in progress
Sign Up For LTRN Email News Alerts
Disclosure
RedChip Companies, Inc. research reports, company profiles, and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that RedChip Companies Inc. is an investor relations firm hired by certain companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles, or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and/or the Ontario Securities Commission (“OSC”) at www.osc.gov.on.ca.
Lantern Pharma (LTRN) is a client of RedChip Companies, Inc. LTRN agreed to pay RedChip Companies, Inc. 50,000 shares of Rule 144 stock for six months of investor awareness services, beginning in March 2026. RedChip intends to and will, if possible, sell all of its shares immediately upon removal of the restriction, and you may be buying as RedChip is selling. Previously, LTRN agreed to pay RedChip an $8,500 monthly cash fee, beginning in June 2025, for three months of investor awareness services, and a $10,000 monthly cash fee, beginning in April 2023, and 2500 shares of Rule 144 stock, for six months of RedChip investor awareness services. The shares were registered and RedChip sold its shares immediately. LTRN also agreed to pay RedChip a one-time $54,000 fee for a 10-day national TV ad campaign aired in June 2025. LTRN also agreed to pay RedChip a $104,000 fee for a six week national TV ad campaign aired weekdays from February 26 through April 15, 2024. RedChip’s president purchased 50,000 shares of LTRN stock at $1.27 per share in March 2026; these shares may be sold at any time, and you may be buying as they are sold.
Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services.